New study to test statin-Parkinson's link

January 15, 2007

Researchers are sufficiently worried by new study results that they are planning clinical trials involving thousands of people to examine the possible link between Parkinson's disease and statins, the world biggest selling drugs, reports Patrick Walter in Chemistry & Industry, the magazine of the SCI.

Suggestions of a statin link are not new, but the results of a recent study linking low LDL cholesterol to Parkinson's provide the strongest evidence to date that it could be real, because statins work by reducing LDL cholesterol. The study by researchers at University of North Carolina showed that patients with low levels of LDL cholesterol are more than three and a half times more likely to develop Parkinson's disease than those with higher LDL levels.

When asked whether she was concerned by the new results, study leader Xuemei Huang said: 'Yes I am very concerned, which is why I am planning a 16000-patient prospective study to examine the possible role of statins.' Huang was quick to point out, however, that a causal link with statins had not yet been proven. And Yoav Ben-Shlomo, a professor of clinical epidemiology at University of Bristol said that it is also a possibility that LDL cholesterol is a consequence rather than a cause of Parkinson's.

But according to Huang, the well-established link between Parkinson's and apoE2, a gene associated with lower LDL cholesterol, supports her theory that low LDL is the culprit in many cases of Parkinson's.

Huang says that if there is a link with statins, we could see big surges in the number of Parkinson's diagnoses in the next five years, because at that stage, statins will have been in common usage for more than a decade.

Huang's new study will examine the statin link. A total of 16000 patients for whom 20 years of baseline fasting cholesterol measurements are available will be involved. Another large-scale trial investigating a cholesterol link with Parkinson's risk is underway at Harvard. This study differs in that there are no baseline data available for the study group.

Pfizer's statin Lipitor is the world's biggest selling drug with $12.2bn in sales in 2005. Parkinson's has previously been linked with pesticides. Pfizer were unavailable for comment.
-end-
Chemistry & Industry

Please acknowledge Chemistry & Industry as the source of these items. If publishing online, please include a hyperlink to http://www.chemind.org Please note Chemistry & Industry uses '&' in its title, please do not correct to 'and'.

About Chemistry & Industry

Chemistry & Industry magazine from SCI delivers news and comment from the interface between science and business. As well as covering industry and science, it focuses on developments that will be of significant commercial interest in five- to ten-years time. Published twice-monthly and free to SCI Members, it also carries authoritative features and reviews. Opinion-formers worldwide respect Chemistry & Industry for its independent insight.

About SCI

SCI is a unique international forum where science meets business on independent, impartial ground. Anyone can join, and the Society offers a chance to share information between sectors as diverse as food and agriculture, pharmaceuticals, biotechnology, environmental science and safety. As well as publishing new research and running events, SCI has a growing database of member specialists who can give background information on a wide range of scientific issues. Originally established in 1881, SCI is a registered charity with members in over 70 countries.

Society of Chemical Industry

Related Statins Articles from Brightsurf:

Being in treatment with statins reduces COVID-19 mortality by 22% to 25%
A research by the Universitat Rovira i Virgili (URV) and Pere Virgili Institut (IISPV) led by LluĂ­s Masana has found that people who are being treated with statins have a 22% to 25% lower risk of dying from COVID-19.

Twitter data research reveals more about what patients think about statins
More than one in seven people taking statins -- prescribed to lower cholesterol levels -- believed that meant they could still eat unhealthy foods, a new study shows.

Statins starve cancer cells to death
More than 35 million Americans take statin drugs daily to lower their blood cholesterol levels.

Statins linked to higher diabetes risk
Individuals who take cholesterol-lowering statins may be at higher risk for developing high blood sugar levels, insulin resistance, and eventually type 2 diabetes, according to an analysis published in the British Journal of Clinical Pharmacology.

Statins could protect against motor neurone disease
High cholesterol has been found to be a possible risk factor for the development of motor neurone disease (MND), according to a large study of genetic data led in the UK by Queen Mary University of London, in collaboration with the National Institutes of Health in the USA.

Statins are more effective for those who follow the Mediterranean diet
For those who have already had a heart attack or a stroke, the combination of statins and Mediterranean Diet appears to be the most effective choice to reduce the risk of mortality, especially from cardiovascular causes.

Statins have low risk of side effects
Cholesterol-lowering statin drugs are associated with a low risk of side effects.

Statins overprescribed for primary prevention
Taking cholesterol-lowering drugs, or statins, as a preventive measure can reduce the risk of cardiovascular disease.

Many older adults do not take prescribed statins properly
In a British Journal of Clinical Pharmacology study of older adults prescribed statins, first-year nonadherence and discontinuation rates were high.

Statins show little promise for conditions other than heart disease
Medicines commonly prescribed to reduce people's risk of heart attack may have limited use for treating other diseases, research suggests.

Read More: Statins News and Statins Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.